Notice of Extraordinary General Meeting of Vitrolife AB (publ)

The shareholders of Vitrolife AB (publ) are hereby invited to the Extraordinary General Meeting of shareholders (“EGM”) on October 20, 2021. The EGM will be held by advance voting (postal voting).

Shareholders who wish to attend the EGM must:

• be entered in the register of shareholders maintained by Euroclear Sweden AB on October 12, 2021 and
   
• notify their attendance by submitting their postal votes in accordance with the instructions in the Notice.

Shareholders that have their shares registered in the name of a nominee must temporarily record their shares in the share register kept by Euroclear Sweden AB in their own names to be able to attend the General Meeting.

The following proposals will be amongst those presented at the EGM:

• The Election Committee proposes that the Board should be extended with one Board member and consist of six Board members.

• Remuneration to the Board members is proposed to be SEK 2,440,000. The proposal entails an increase of SEK 275,000 due to the proposed increased number of Board members.

• The Election Committee proposes election of Vesa Koskinen, Partner and member of the global healthcare sector team at EQT, as a new Board member.

• The Board of Directors proposes that the General Meeting resolves to approve the Board's proposal on a new issue of shares (non-cash issue) related to the acquisition of Igenomix (see press release dated July 8, 2021).

Attachment: Full notice

Gothenburg, September 29, 2021
VITROLIFE AB (publ)
The Board

Contact:
Jón Sigurdsson, Chairman of the Board, email: jsigurdsson@ossur.com
Mikael Engblom, CFO, phone +46 31 721 80 14

The information was submitted for publication, through the agency of the contact person set out above, at 10.00 am CET on September 29, 2021. 

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

_________________________________________________________________________________________________________________

Vitrolife is an international medical device Group. Vitrolife develops, produces and markets medical devices for assisted reproduction.

Vitrolife has approximately 400 employees and the company's products are sold in about 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in Australia, Belgium, China, Denmark, France, Germany, Italy, Japan, United Kingdom and USA. The Vitrolife share is listed on NASDAQ Stockholm.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail: info@vitrolife.com. Website: www.vitrolife.com/